GlassScriptPhysician profile
Heidi F Meredith
NPI 1538191754
$2,589.61
in general payments reported to CMS, 2019-2025
26 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,639 · 2020: $261 · 2021: $28.29 · 2022: $39.55 · 2023: $60.52 · 2024: $320 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $622.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $400.91 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $384.18 | 2019-2025 | Invega Sustenna |
| Abbvie INC. | $283.79 | 2021-2025 | |
| Lundbeck LLC | $195.06 | 2019-2024 | Abilify Asimtufii |
| Allergan, INC. | $177.67 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $167.05 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $147.06 | 2019-2024 | Trintellix |
| Alkermes, INC. | $109.26 | 2019-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $62.01 | 2019-2025 | Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.96 | 2024-2025 | Caplyta |
| Shire North American Group INC | $60.59 | 2019 | |
| Tris Pharma INC | $58.92 | 2019-2023 | Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $55.00 | 2019 | |
| Bausch Health US, LLC | $50.87 | 2019-2020 | |
| Novo Nordisk INC | $49.74 | 2024 | Wegovy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Owp Pharmaceuticals, INC. | $47.88 | 2019 | |
| Avanir Pharmaceuticals, INC. | $44.94 | 2019 | |
| Ironshore Pharmaceuticals INC. | $41.97 | 2019 | |
| Neos Therapeutics, LP | $36.73 | 2019-2020 | |
| Corium, LLC | $33.09 | 2025 | Azstarys |
| Harmony Biosciences LLC | $31.37 | 2025 | |
| Livanova USA, INC. | $20.07 | 2019 | |
| Acadia Pharmaceuticals INC | $19.56 | 2020 | |
| Alfasigma USA, INC. | $17.63 | 2020 | |
| Vertical Pharmaceuticals, LLC | $17.59 | 2019 | |
| Adlon Therapeutics L.P. | $14.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Meredith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.